Resources
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a disease in which the heart muscle becomes thickened, making it harder for the heart to pump blood.
Hypertension
High blood pressure increases risk for stroke, heart attack and kidney failure. It can also cause many other complications.
High Cholesterol
Cholesterol is a fatty substance in the blood. Some cholesterol is necessary, but too much can clog arteries and may cause a heart attack or stroke.
Peripheral Artery Disease
Peripheral artery disease (PAD) is a condition in which arteries are narrowed and there is reduced blood flow to the arms or legs. PAD is usually a sign of a buildup of fatty deposits in the arteries. This can cause pain in these extremities.
New Hypertension Treatments Give Patients Options
More than 100 million Americans have hypertension. Nearly a third have uncontrolled hypertension—when a patient is taking 3 or more medications with little blood pressure improvement.
A MINI Act Could Be Big for Patients
Game-changing medical technology is on the line. Based on Nobel-prize winning science, genetically targeted technologies take on the proteins that cause disease. The medications are administered once or twice a year to treat rare and debilitating diseases, from Duchenne muscular dystrophy to high cholesterol.
Fail First is Failing Heart Disease Patients
As rates of heart attack and stroke soar, now is the time for policymakers to ensure that heart patients get the right medicine at the right time.
CMS Semaglutide Obesity Coverage
Letter to CMS on the need for obesity treatment coverage.
CMS Semaglutide Coverage Expansion Could Save Millions of Lives, Advocates Say
44 organizations across various disease states support an expansion of semaglutide coverage for Medicare and Medicaid patients.
Alternative Funding Programs
Alternative funding programs come at a significant cost to patients and the health care system.
Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the U.S. Inflation Reduction Act
To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for […]
Alternative Funding Programs
Alternative funding programs come at a significant cost to patients and the health care system.